Metabolic disparities between obese and non-obese patients with polycystic ovary syndrome: implications for endometrial receptivity indicators
- PMID: 38444321
- DOI: 10.1080/09513590.2024.2312895
Metabolic disparities between obese and non-obese patients with polycystic ovary syndrome: implications for endometrial receptivity indicators
Abstract
Objective: To investigate the differences in the metabolic indicators and sex hormones between obese and non-obese patients with polycystic ovary syndrome (PCOS), and their impacts on endometrial receptivity (ER).
Methods: We selected 255 individuals with PCOS, and categorized them into the obese groups, including the OP group (obese patients with PCOS) and the ON group (obese patients without PCOS), and selected 64 individuals who were categorized in the non-obese groups, namely, the control groups, which comprise the NP group (non-obese patients with PCOS) and the NN group(non-obese patients without PCOS). The one-way analysis of variance (ANOVA) and Mann-Whitney U tests were used to compare the metabolic indicators, and sex hormone-associated and ER-associated indicators between the groups. The correlation between the aforementioned clinical markers and ER was analyzed using the Pearson's correlation coefficient.
Results: (1) In comparison with the NP group, the OP group exhibited higher levels (p < .01) of free androgen index (FAI), anti-müllerian hormone (AMH), fasting insulin (FINS), insulin level within 60 min, 120 min, and 180 min-60minINS, 120minINS, and 180minINS, respectively, fasting blood glucose (FBG), blood glucose level within two hours (2hGlu), homeostatic model assessment for insulin resistance (HOMA-IR), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), waist-to-hip ratio (WHR), waist circumference, hip circumference, the ratio of the maximum blood flow velocity of the uterine artery during systole to the blood flow velocity of the uterine artery at the end of diastole (uterine artery S/D), and blood flow resistance index (RI) of the uterine artery. In comparison with the NP group, the OP group exhibited lower levels (p < .01) of sex hormone binding globulin (SHBG), dehydroepiandrosterone (DHEA), high molecular weight adiponectin (HMWA), and high-density lipoprotein cholesterol (HDL-C). (2) In the PCOS group, RI was significantly positively correlated with FAI, FINS, 120minINS, HOMA-IR, and WHR (p < .01), and significantly negatively correlated with SHBG, HDL-C, and HMWA (p < .01); uterine artery S/D was significantly positively correlated with FAI, FINS, 2hGlu, HOMA-IR, LDL-C, and WHR (p < .01), significantly positively correlated with 120minINS and FBG (p < .05), and significantly negatively correlated with SHBG and HMWA (p < .01).
Conclusion: (1) The OP group exhibited obvious metabolic disorders and poor ER, which was manifested as low levels of SHBG and HMWA, and high levels of FAI, HOMA-IR, WHR, uterine artery S/D, and RI. (2) In patients with PCOS, there was a substantial correlation between ER-associated indicators RI and uterine artery S/D and FAI, FINS, 120minINS, HOMA-IR, WHR, SHBG, and HMWA.
Keywords: Obesity; endometrial receptivity (ER); polycystic ovary syndrome (PCOS); free androgen index (FAI); insulin resistance (IR); adiponectin.
Similar articles
-
[Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].Zhonghua Yi Xue Za Zhi. 2005 Dec 7;85(46):3266-71. Zhonghua Yi Xue Za Zhi. 2005. PMID: 16409817 Chinese.
-
Evaluation of carotid artery elasticity and its influencing factors in non-obese PCOS patients using a technique for quantitative vascular elasticity measurement.Front Endocrinol (Lausanne). 2024 Sep 9;15:1374718. doi: 10.3389/fendo.2024.1374718. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39314523 Free PMC article.
-
Are serum chemerin levels different between obese and non-obese polycystic ovary syndrome women?Gynecol Endocrinol. 2016;32(1):38-41. doi: 10.3109/09513590.2015.1075501. Epub 2015 Aug 18. Gynecol Endocrinol. 2016. PMID: 26291816
-
Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis.J Obstet Gynaecol. 2017 Nov;37(8):1036-1047. doi: 10.1080/01443615.2017.1318840. Epub 2017 Jun 28. J Obstet Gynaecol. 2017. PMID: 28657375 Review.
-
Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Polycystic Ovary Syndrome in East Asia: A Review and Meta-Analysis.Endocr Pract. 2025 May;31(5):668-676. doi: 10.1016/j.eprac.2025.01.011. Epub 2025 Feb 11. Endocr Pract. 2025. PMID: 39947624 Review.
Cited by
-
Is it feasible to treat polycystic ovarian syndrome with or without insulin resistance using glucokinase activators as novel hypoglycaemic medications? A protocol for a systematic review and meta-analysis.BMJ Open. 2024 Dec 22;14(12):e088484. doi: 10.1136/bmjopen-2024-088484. BMJ Open. 2024. PMID: 39806679 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous